Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

WTX-330

Fusion protein · Immune activation · developed by Werewolf Therapeutics

Phase 1/2 Most advanced trial
HOWL Developer
1 Registered trials

What is WTX-330?

WTX-330 is an engineered prodrug form of the human cytokine interleukin-12, with IL-12 held inactive by a blockade element linked through a tumor protease-sensitive linker and a half-life extension domain. Proteolytic cleavage in the tumor microenvironment releases active IL-12, which promotes IFN-gamma secretion and activates CD8+ T-cells, CD4+ T-cells and natural killer cells. It is studied in advanced or metastatic solid tumors and non-Hodgkin lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Fusion protein
Mechanism
Immune activation
Pathways
IFN-gamma secretion, CD8+ T-cell activation, CD4+ T-cell activation, natural killer cell activation
Therapy area
Oncology
Developer
Werewolf Therapeutics, Inc. (HOWL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06939283 Phase 1/2 Advanced or Metastatic Solid Tumors Completed HOWL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced or Metastatic Solid TumorsNon-Hodgkin Lymphoma

More from Werewolf Therapeutics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the HOWL page.

Follow HOWL, the company behind WTX-330

See HOWL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

HOWL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.